Outcomes Of Newly Diagnosed Stage Ii Ovarian, Primary Peritoneal And Fallopian Tube Cancer Receiving Intravenous Or Intraperitoneal Platinum Based Chemotherapy In Combination With Veliparib And Bevacizumab

Objective: The aim of this study was to determine progression-free survival (PFS) and overall survival (OS) among stage II epithelial ovarian, peritoneal, or fallopian tube cancer (EOC) patients enrolled on GOG 9923 a phase I study every 21-day carboplatin/paclitaxel (C/T), weekly C/T or intravenous and intraperitoneal paclitaxel/cisplatin (IP) in combination with continuous or intermittent ABT-888 and bevacizumab in newly diagnosed previously untreated EOC.